In order to assess the safety, feasibility, and immunogenicity of the VEGFR peptide-based vaccine targeting tumor angiogenesis, we performed a pilot study for HLA-A2402 patients with recurrent/progressive high grade gliomas. The gene discussed is KDR; the disease is neoplasm.